Axa S.A. Veracyte, Inc. Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Veracyte, Inc. stock. As of the latest transaction made, Axa S.A. holds 125,102 shares of VCYT stock, worth $4.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

125,102

Previous 16,010 681.4%

Holding current value

$4.5 Million

Previous $346,000 1130.35%

% of portfolio

0.01%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $2.29 Million - $3.85 Million	109,092 Added 681.4%	125,102 $4.26 Million
Q2 2024 Aug 14, 2024	BUY	$18.86 - $23.55 $301,948 - $377,035	16,010 New	16,010 $346,000
Q2 2022 Aug 15, 2022	SELL	$15.45 - $29.52 $1.45 Million - $2.76 Million	-93,618 Closed	0 $0
Q1 2022 Feb 14, 2023	BUY	$21.94 - $42.51 $2.05 Million - $3.98 Million	93,618 New	93,618 $2.58 Million
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $33,708 - $50,239	934 Added 1.01%	93,618 $3.86 Million
Q1 2021 May 14, 2021	SELL	$44.47 - $81.38 $592,162 - $1.08 Million	-13,316 Reduced 12.56%	92,684 $4.98 Million
Q4 2020 Feb 12, 2021	SELL	$32.49 - $61.88 $4.84 Million - $9.22 Million	-149,000 Reduced 58.43%	106,000 $5.19 Million
Q3 2020 Nov 13, 2020	BUY	$26.73 - $35.67 $2 Million - $2.66 Million	74,700 Added 41.43%	255,000 $8.29 Million
Q2 2020 Aug 14, 2020	BUY	$19.49 - $28.11 $37,323 - $53,830	1,915 Added 1.07%	180,300 $4.67 Million
Q1 2020 May 15, 2020	BUY	$16.13 - $30.17 $196,544 - $367,621	12,185 Added 7.33%	178,385 $4.34 Million
Q4 2019 Feb 18, 2020	SELL	$20.78 - $29.99 $1.09 Million - $1.57 Million	-52,450 Reduced 23.99%	166,200 $4.64 Million
Q3 2019 Nov 14, 2019	BUY	$23.87 - $30.93 $5.22 Million - $6.76 Million	218,650 New	218,650 $5.25 Million

Others Institutions Holding VCYT

# of Institutions

307

Shares Held

81.7M

Call Options Held

134K

Put Options Held

13.3K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.57B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account